Cargando…
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Dysregulation of Fibroblast Growth Factor Receptor (FGFR) signaling through amplifications, mutations, and gene fusions has been implicated in a broad array of cancers (e.g. liver, gastric, ovarian, endometrial, and bladder). ARQ 087 is a novel, ATP competitive, small molecule, multi-kinase inhibito...
Autores principales: | Hall, Terence G., Yu, Yi, Eathiraj, Sudharshan, Wang, Yunxia, Savage, Ronald E., Lapierre, Jean-Marc, Schwartz, Brian, Abbadessa, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023172/ https://www.ncbi.nlm.nih.gov/pubmed/27627808 http://dx.doi.org/10.1371/journal.pone.0162594 |
Ejemplares similares
-
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017) -
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015) -
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017) -
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
por: Papadopoulos, K P, et al.
Publicado: (2017) -
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)